SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
Consumer |
Outlook
Consumer |
Update
Consumer |
Update
Consumer |
QuickView
Daniel Kruse
CEO
% | 1M | 3M | 12M |
---|---|---|---|
Actual | (21.8) | 150.6 | 83.3 |
Relative | (19.3) | 136.2 | 62.7 |
52 week high/low | €13.9/€2.9 |
SynBiotic’s management has created a platform that spans the value chain in the cannabis and cannabinoid space, from cultivation and labs to distribution. SynBiotic’s business creates and markets cannabis and cannabinoid products, which have both medical and consumer applications, with management constantly looking to add to its portfolio. We believe SynBiotic is well-placed to benefit from any relaxation in legislation around cannabis and cannabinoid products in Germany, as per the published government white paper (Eckpunktepapier), as it already operates across the cannabis value chain and has expertise in the field.